LUCID DIAGNOSTICS INC. LUCD 深 滬
等待開盤 11-26 09:30:00 美东时间
1.09
+0.030
+2.83%
華盛通- 最 高1.10
- 今 開1.06
- 成交量 103.43万股
- 最 低 1.03
- 昨 收 1.06
- 總市值 1.43亿
- 52周最高 1.80
- 市盈率 靜 --
- 換手率 0.79%
- 52周最低 0.7501
- 委 比 -55.51%
- 總股本 1.31亿
- 歷史最高 13.52
- 量 比 1.41
- 振 幅 6.60%
- 歷史最低 0.6301
- 每 手 1
- 風險率 0.21%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 思科、On Holding、派拓网络等获多家机构上调目标价；Circle 遭富国、德银等多家机构下调目标价
今日重点评级关注：HC Wainwright & Co.：维持PDS Biotechnology"买入"评级，目标价从13美元升至15美元；HC Wainwright & Co.：维持PepGen Inc."买入"评级，目标价从18美元升至20美元
11-14 10:43
Needham Reiterates Buy on Lucid Diagnostics, Maintains $3 Price Target
Needham analyst Mike Matson reiterates Lucid Diagnostics (NASDAQ:LUCD) with a Buy and maintains $3 price target.
11-13 19:00
Lucid Diagnostics Q3 Adj. EPS $(0.10) Beats $(0.11) Estimate, Sales $1.211M Miss $1.357M Estimate
Lucid Diagnostics (NASDAQ:LUCD) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.11) by 9.09 percent. This is a 50 percent increase over losses of $(0.20) per share from the
11-12 21:09
Earnings Scheduled For November 12, 2025
Companies Reporting Before The Bell • Hudbay Minerals (NYSE:HBM) is projected t...
11-12 19:11
美股大行评级 | 潜在涨幅4347.41%！Ascendiant Capital上调PAVmed目标价至20美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持PAVmed"买入"评级，目标价从19美元升至20美元；Ascendiant Capital：维持Plus Therapeutics"买入"评级，目标价从20.5美元升至21美元
10-07 15:04
Ascendiant Capital Maintains Buy on Lucid Diagnostics, Raises Price Target to $8
Ascendiant Capital analyst Edward Woo maintains Lucid Diagnostics (NASDAQ:LUCD) with a Buy and raises the price target from $7.75 to $8.
10-06 18:06
Lucid Diagnostics Appoints John R. Palumbo to Board
The latest announcement is out from Lucid Diagnostics ( ($LUCD) ). On September...
09-25 21:17
美股大行评级 | 最高400美元！大行纷纷连夜上调甲骨文目标价；新思科技则惨遭多家大行下调目标价
今日重点评级关注：瑞银：上调Gossamer Bio评级至"买入"，目标价从1.25美元升至9美元；Canaccord Genuity：维持Corcept Therapeutics"买入"评级，目标价从137美元升至140美元
09-11 10:06
Lucid Diagnostics dips after pricing $25M stock offering
Lucid Diagnostics (NASDAQ:LUCD) fell over 17% premarket on Wednesday after it priced a public offering of 25 million shares at $1.00 each. Underwriters also have a 30-day option to buy up to 3.75 mill...
09-10 20:29
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Revelation Biosciences (NASDAQ:REVB) stock moved upwards by 7.7% to $2...
09-10 05:06
